Eli Lilly and Company $LLY Stock Sold by Calamos Wealth Management LLC

Calamos Wealth Management LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,480 shares of the company’s stock after selling 697 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Calamos Wealth Management LLC’s holdings, making the stock its 22nd biggest position. Calamos Wealth Management LLC’s holdings in Eli Lilly and Company were worth $35,268,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Calamos Advisors LLC boosted its position in shares of Eli Lilly and Company by 2.2% in the third quarter. Calamos Advisors LLC now owns 289,232 shares of the company’s stock worth $334,665,000 after buying an additional 6,231 shares during the period. Financial Council LLC increased its stake in Eli Lilly and Company by 0.6% in the 3rd quarter. Financial Council LLC now owns 1,255 shares of the company’s stock valued at $1,452,000 after buying an additional 8 shares during the period. Burke & Herbert Bank & Trust Co. grew its holdings in shares of Eli Lilly and Company by 0.5% during the 3rd quarter. Burke & Herbert Bank & Trust Co. now owns 5,255 shares of the company’s stock valued at $6,080,000 after acquiring an additional 24 shares in the last quarter. Alta Advisers Ltd raised its holdings in shares of Eli Lilly and Company by 85.0% during the third quarter. Alta Advisers Ltd now owns 5,697 shares of the company’s stock worth $6,592,000 after acquiring an additional 2,618 shares in the last quarter. Finally, Birchwood Financial Partners Inc. grew its stake in Eli Lilly and Company by 10.9% in the third quarter. Birchwood Financial Partners Inc. now owns 203 shares of the company’s stock valued at $235,000 after purchasing an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $7.42 during mid-day trading on Friday, reaching $1,372.15. The company’s stock had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,453.00. The company has a market cap of $1.29 trillion, a P/E ratio of 44.54, a PEG ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm’s 50-day moving average is $1,215.24 and its two-hundred day moving average is $1,101.16.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.02 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Scotiabank raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Royal Bank Of Canada raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a report on Tuesday, September 15th. Finally, HSBC increased their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $17,020,770 in the last quarter. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.